Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR Names New Editor-in-chief of Molecular Cancer Therapeutics

4/9/2019

PHILADELPHIA — The American Association for Cancer Research (AACR) is pleased to announce the appointment of Beverly Teicher, PhD, as editor-in-chief of Molecular Cancer Therapeutics, one of eight highly esteemed journals published by the AACR. She officially began her term as editor-in-chief of Molecular Cancer Therapeutics on Jan. 1. 

Molecular Cancer Therapeutics publishes the best science in the design, synthesis, discovery, and preclinical study of novel therapeutic agents for the treatment or prevention of cancer. 

“Dr. Teicher is a world-renowned expert in the field of molecular therapeutic research, and the American Association for Cancer Research is thrilled to welcome her as editor-in-chief of Molecular Cancer Therapeutics,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “With almost 40 years of extensive research experience and contributions to the field, she will enhance the impact of this remarkable journal through her leadership and will further advance our mission to prevent and cure all cancers.”  

Teicher is chief of the Molecular Pharmacology Branch at the National Cancer Institute, focusing on target and drug discovery in the disease areas of sarcoma and small cell lung cancer. She is best known for her work in solid tumor models and physiologic measurements of tumor hypoxia and oxygenation, the study of antiangiogenic agents, and the study of drug combinations with an emphasis on in vivo determination of tumor cell killing along with determination of bone marrow CFU-GM killing in the same host. She has led laboratories and teams that have contributed critical preclinical studies to several approved anticancer agents and several investigational agents currently in clinical trial. 

Teicher has been an active member of the AACR since 1981, having served as a senior editor of Clinical Cancer Research and, more recently, as a senior editor of Molecular Cancer Therapeutics before being named editor-in-chief. She is also a member of the Stand Up To Cancer-Melanoma Research Alliance Joint Scientific Advisory Committee. The AACR is the Scientific Partner of Stand Up To Cancer. 

“I am grateful for the opportunity to lead this journal at a time when improving therapeutics for cancer treatment is essential,” Teicher said. “I look forward to continuing to expand and strengthen its influence within the drug discovery community, as well as within the wider research community.”

Teicher completed a doctorate in bioorganic chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. She is active in the international scientific community, having authored or coauthored more than 400 scientific publications and edited eight books. She is a member of the American Chemical Society, the Radiation Research Society, and the American Association for the Advancement of Science. She is the recipient of numerous awards and honors, including the Lilly Research Laboratories President’s Award (2011), the American Cancer Society Junior Faculty Award (1999), and the National Chemistry Honorary (1976).